Evidence map›Paper›PMID 33779572›Full record

ArticleJMIR formative research2021

Global Collaborative Social Network (Share4Rare) to Promote Citizen Science in Rare Disease Research: Platform Development Study.

Roxana Radu, Sara Hernández-Ortega, Oriol Borrega, Avril Palmeri, Dimitrios Athanasiou, Nicholas Brooke, Inma Chapí, Anaïs Le Corvec, Michela Guglieri, Alexandre Perera-Lluna and 3 more

Abstract read
In one paragraph

Article in JMIR formative research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Roxana RaduThe Synergist, Brussels, Belgium.ORCID https://orcid.org/0000-0002-0349-7273
Sara Hernández-OrtegaSant Joan de Déu Research Institute, Esplugues de Llobregat, Spain.ORCID https://orcid.org/0000-0002-0335-7641
Oriol BorregaOmada Interactiva SL, Barcelona, Spain.ORCID https://orcid.org/0000-0003-1092-9924
Avril PalmeriJohn Walton Muscular Dystrophy Research Centre, Newcastle University, Newcastle, United Kingdom.ORCID https://orcid.org/0000-0002-6171-5793
Dimitrios AthanasiouStichting United Parent Projects Muscular Dystrophy, World Duchenne Organization, Amsterdam, Netherlands.ORCID https://orcid.org/0000-0002-1140-1286
Nicholas BrookeThe Synergist, Brussels, Belgium.ORCID https://orcid.org/0000-0002-7374-8920
Inma ChapíOmada Interactiva SL, Barcelona, Spain.ORCID https://orcid.org/0000-0002-8999-9038
Anaïs Le CorvecClicLab, Barcelona, Spain.ORCID https://orcid.org/0000-0003-2788-9180
Michela GuglieriJohn Walton Muscular Dystrophy Research Centre, Newcastle University, Newcastle, United Kingdom.ORCID https://orcid.org/0000-0002-8455-0637
Alexandre Perera-LlunaCenter for Biomedical Engineering Research, Universitat Politècnica de Catalunya, Barcelona, Spain.ORCID https://orcid.org/0000-0001-6427-851X
Jon Garrido-AguirreCenter for Biomedical Engineering Research, Universitat Politècnica de Catalunya, Barcelona, Spain.ORCID https://orcid.org/0000-0002-7928-6376
Bettina RyllMelanoma Patient Network Europe, Uppsala, Sweden.ORCID https://orcid.org/0000-0002-2652-8474
Begonya Nafria Escalera *Sant Joan de Déu Research Institute, Esplugues de Llobregat, Spain.ORCID https://orcid.org/0000-0002-4494-3663

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRare disease communities are spread around the globe and segmented by their condition. Little research has been performed on the majority of rare diseases. Most patients who are affected by a rare disease have no research on their condition because of a lack of knowledge due to absence of common groups in the research community.

objectiveWe aimed to develop a safe and secure community of rare disease patients, without geographic or language barriers, to promote research.

methodsCocreation design methodology was applied to build Share4Rare, with consultation and input through workshops from a variety of stakeholders (patients, caregivers, clinicians, and researchers).

resultsThe workshops allowed us to develop a layered version of the platform based on educating patients and caregivers with publicly accessible information, a secure community for the patients and caregivers, and a research section with the purpose of collecting patient information for analysis, which was the core and final value of the platform.

conclusionsRare disease research requires global collaboration in which patients and caregivers have key roles. Collective intelligence methods implemented in digital platforms reduce geographic and language boundaries and involve patients in a unique and universal project. Their contributions are essential to increase the amount of scientific knowledge that experts have on rare diseases. Share4Rare has been designed as a global platform to facilitate the donation of clinical information to foster research that matters to patients with rare conditions. The codesign methods with patients have been essential to create a patient-centric design.

Indexed as

citizen sciencegenotypenatural historyparticipatory medicinephenotyperare diseaseShare4Rare

Identifiers

PMID33779572
PMCPMC8088870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.